TDB opens the purse for biotech firmsIn recent years, the Technology Development Board (TDB) in the Department of
Science and Technology (DST) has emerged as the major funding organization for
the biotechnology sector. TDB was set up on September 1, 1996, to channel the
funds generated through a 5 percent cess levied on all technology imports into
India. The board draws its powers from the Technology Development Board Act,
1995.
TDB invests in equity capital or gives soft loans to
industrial units, cooperatives and other agencies, as applicable, attempting
development and commercial application of indigenous technology, or adapting
importing technology to wider domestic applications. The board invests up to 25
percent in equity shares of the total project cost, including margin money for
working capital. However, this investment will not exceed the paid-up share
capital of the promoters. In some cases, instead of equity shares, soft loans at
5 percent annual interest rate is given on the basis of collateral guarantees
for the duration of the project up to a maximum of three years. The repayments
have to be done in five years and it starts a year after the completion of the
project.
A strong linkage with government institutions is a must. For
projects involving commercialization of technologies developed by a government
institution, the company applying for assistance should have an agreement with
the technology developing organization. TDB will also provide assistance to
projects for commercialization developed with the financial support under the
Home Grown Technology/mission projects/Technology Vision 2020 implementation
projects of the Technology Information, Forecasting and Assessment Council (TIFAC).
Projects supported by other government projects like the PATSER (Program Aimed
at Technological Self Reliance) of the Department of Scientific and Industrial
Research (DSIR) or the Technopreneur Promotion Program (TePP).
Where legal title to domestically generated intellectual
property is held by an inventor of such property or by an industrial concern,
such individual or industrial concern is also eligible to apply. In the case of
commercializing imported technology, the board provides financial assistance
mainly for effecting crucial modifications for wider domestic applications
through a recognized R&D institution or through an individual or industrial
concern and for further development of commercializable technology, imported
when that technology is at "proof of concept" or design stage.
However, funding from the TDB is not available for
refinancing, basic research, establishment of new R & D centers, any forms
of grants-in-aid or loan for the mere creation of technical infrastructure and
more than two projects at one time to an industrial enterprise.
| Enterprise |
Project Cost |
TDB Assistance |
Project |
| Shanta Biotechnics |
INR 252.6 mn |
INR 85 mn (33 percent of total cost) |
Development and commercialization of recombinant Hepatitis B
Vaccine |
Shanta Biotechnics
|
INR 244 mn |
INR 122mn (50 percent of total cost) |
Development and commercialization of recombinant human
Interferon alpha 2
|
| Bharat Biotech |
INR 1221.1mn |
INR 32.5 mn |
Development and commercialization
of recombinant Hepatites B Vaccine |
| Bharat Biotech |
INR 235 mn |
INR 110 mn (46.8 percent of |
Development and commercialization of recombinant
Sreptokinase
|
| Mark Medicines |
INR 265.7 mn |
INR 70 mn (26.3 percent of total cost) |
Commercialization of Biobacton - a contrate of living
lactic acid bacteria total cost) possessing high probiotic and acidogenic
qualities is used for preventing the development of conditional pathogenic
and eteropathogenic flora in the intestine. The technology has been
provided by Ministry of Atomic Energy, Russian Federation |
| Prathista Industries |
INR 104.6 mn |
INR 40 mn (38 percent of total cost) |
Manufacture of Gluconic Acid and its salts through
cost-effective fermentation process developed by Regional Research
Laboratory, Jammu |
| Shantha Marine Biotechnologies Pvt. Ltd. |
INR 95 mn |
INR 35 mn (36.8 percent of Cost) |
Extraction of natural Beta Carotene by setting up the
production facilities for cultivation of Marine Micro Algea Dunaliella
Salina in sea water with technology from ABL Biotechnologies Ltd. |
| Ajay Biotech (India) Ltd. |
INR 25mn |
INR 12.5mn (50 percent of total cost) |
Development, scale-up and manufacture of bio-pesticide based
on Bacillus thruingiensi (Bt) |
| SPIC Ltd. |
INR 25 mn |
INR 11.3 mn |
Commercialization of technology for production of industrial
enzymes-Alpha-amylase and Tannase |
| Javeri Agro Industrial & Investment Co.Ltd |
INR 16.3 mn |
INR 4 mn (24.4 percent of total cost) |
Manufacture of Rhizobium based bio-fertiliser and
Trichoderma (bio-control agent) |
Next Page : List of biotech venture capitalists
Page(s) 1 2 3 4 5 6 7 |